Spokes person of DRAP 22nd
meeting of the Policy Board of DRAP was held on 23rd October, 2017 under the
chairmanship of Federal Secretary NHS,R&C. The meeting was attended by the
provincial Secretaries of health or their representatives from government of
Punjab, Sindh, KPK, Baluchistan and FATA, as well as by expert members of the
Board.
Policy Board in addition to routine functions granted the approval of
Pharmaco vigilance Regulations, 2017 as recommended by the Authority.
Under these regulations a
National Pharmaco vigilance centre will be establish to collect data of adverse
drugs reactions, as a continuous monitoring and vigilance of marketed drugs, in
line with international practices, for patient safety. Registration
holders of medicines will submit data of Adverse drugs reactions from their
products to National Pharmaco vigilance centre. In addition to pharmaceutical
companies, medical professional’s doctors, Pharmacists, Nurses will also submit
pharmaco vigilance data. Furthermore, a new portal will be available for
patients / public to report a drug complaint or adverse report. Provincial
chapters will also be established and will be linked for monitoring and early
detection of any potential drug related adverse event.
This centre will also be linked with Uppsala monitoring centre of World
health organization and thus, medical professionals of Pakistan will have
access to the updated information on drugs.
The Board approved in principle the draft guideline for code for
pharmaceutical industry for ethical marketing and interaction with healthcare
professional. DRAP will share these drafts with stakeholders before final
notification. In addition, for consistent improvements towards international
practices and strengthening of DRAP, a Quality Management Cell was approved
along with Vigilance Cell in DRAP.
The annual price increase for 2017-2018, based on Consumer Price
Index (CPI) of 4.16% as announced by Statistical Bureau of Pakistan, the
increase in schedule drug of around 2.08% and 2.91% for non-schedule drugs
category in accordance to the Drug Pricing Policy, 2015, that was approved by
the ECC. The DPC has recommended the subject annual price increase as per Drug
Pricing Policy 2015. The Board was informed its implementation in accordance to
the Policy.